News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
$2.6M to ex-CEO Hurts AVI BioPharma, Inc. in Q2
August 10, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Puget Sound Business Journal -- A one-time $2.6 million charge related to the departure of ex-CEO Leslie Hudson hurt AVI BioPharma Inc.’s second-quarter results.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Sarepta Therapeutics, Inc.
MORE ON THIS TOPIC
Business
J&J’s Duato makes 358 times his median employee; Vertex CEO makes just 80 times
May 20, 2026
·
1 min read
·
Annalee Armstrong
Job Trends
Takeda cuts send layoffs soaring in May, rising year over year
May 19, 2026
·
4 min read
·
Angela Gabriel
Drug Development
Is Revolution ‘the next oncology titan’? Truist analysts make the case
May 18, 2026
·
3 min read
·
Heather McKenzie
Deals
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
May 18, 2026
·
2 min read
·
Gabrielle Masson
